Sun Pharma Share Price Target 2024, 2025, 2027, 2030, 2040

If you think about which share will be best for investment in recent times then you should know about Sun Pharma Share Price Target. Today in our blog we will explain the basic idea about Sun Pharma Share Price Target 2024, 2025, 2027, 2030, 2040. We did the research and took advice from experts to make this blog about the company’s growth, performance, etc.

Sun Pharma Share Price Target is a trading share in the share market. In this article, we will discuss the company’s financial growth, the business policy of the company, the shareholding pattern of the company, and the forecast share price yearly. We use expert data and analysis to understand Sun Pharma Share Price Target. This article may be helpful to those who want to invest in this share right now. Let’s look at Sun Pharma Share Price Target 2024 to 2040.

What Is Sun Pharmaceutical Industries Limited?

Sun Pharma is an Indian multinational pharmaceutical company that was founded in the year 1983. The headquarters of the company is situated in Mumbai. The company’s main function is to manufacture and distribute pharmaceutical formulations and active pharmaceutical ingredients to more than 100 countries.

Overview Of Sun Pharma Company

Sun Pharma Company is one of the largest pharmaceutical company all over India. The company supplies pharmaceutical products for the treatment purposes of neurology, cardiology, nephrology, urology, gynecology, respiratory, oncology, ophthalmology, oncology, dental and nutrition, and many other purposes. The company has 43 manufacturing units all over India and the company holds the 4th largest position for supplying generic drugs.

Most of the revenue of the company is generated from international markets. Around 70% revenue of the company is generated from international markets, mainly 60% of the company’s total turnover comes from the largest market of India and the USA. The employee number of the company is more than 41000 all over India. The company has a market in Brazil, Mexico South Africa, Canada, Japan, China, New Zealand, and more than 80 markets all over India.

Financial Data Analysis Of Sun Pharma Company

Before investing any share anyone wants to see the company’s performance, overall profit, and net sales amount. We need a basic idea about the company’s PE ratio, return on assets, current ratio, and return on equity. In the below portion, we discuss the performance of the company. Sun Pharma Share Price Target also depended upon the ratio which is described below.

History Of Sun Pharma Share Price Target From The Year 2024 to 2040

Sun Pharma Share is a bullish trend in the share market. Sun Pharma Share is under both the Indian Stock Exchange BSE (Bombay Stock Exchange) and NSE (National Stock Exchange). In the last 6 months, the share growth was +277.00 (21.32%), the last 1 year’s share growth was +498.40 (46.25%), the last 5 year’s share growth was +1,154.65 (274.04%), the maximum share growth was +1,573.73 (69,412.67%), and in the last 1 month the share growth declined by +55.05 (3.62%) but in coming future the share rate will grow.

The last 3 months’ share price return amount was 2.73%, the last 1 year’s share price return amount was 46.57%, and the last 3 years’ share return amount was 129.35%. Sun Pharma share always gives good returns to investors it will be profitable long-term. Let’s have a look at Sun Pharma Share Price Target from the year 2024 to 2040.

Also Read – Gland Pharma Share Price Target

Sun Pharma Share Price Target 2024

The Indian Pharmaceutical company is one of the fastest-growing Industries. In the last few decades, the most demanding product portfolio of the company has been the medicine of chronic and acute treatment. These products give the higher pricing majority from the financial year 2009 to 2019 this special majority of products increase the pharmaceutical market by 24% to 45%. In the year 2020, Sun Pharma Company launched in China Market Tildarkizumab (used in arthritis) and Cyclospoine (eye drops) for global market expansion.

The revenue of Sun Pharma company also increasing. The total revenue amount was ₹17,456.89 Crore in March 2022 which became ₹22,023.56 Crore in March 2023. The net revenue from operation was ₹16,789.56 Crore in March 2022 which became ₹21,456.89 Crore in March 2023. The EBITDA Margin improved to 20.1% from the financial year 2018 to 27.15% in the year 2022. If we look at the share price forecast of Sun Pharma Share Price Target 2024, the 1st Price Target is ₹1440, and the 2nd Price Target is ₹1765.

Sun Pharma Share Price Target 2025

Sun Pharma Company also provides a wide range of consumer health care products like Revital (Vitamin), Volini (topical analgesics), Faringosept (sore throat), Chericof (cough), Gestid (digestive), Coldact & Flustat (cold & flu), Aspenter, etc. Sun Pharma is in the top 10 consumer healthcare centers that supply its products in 20 emerging markets including Romania, Nigeria, and Myanmar, and distributes products through retail, pharmacy, and online platforms.

Last year’s profit growth of the company increasing a high rate. The last 5 year’s profit growth was 41.25% which decreased by -19.89 % but the last year’s profit growth increased by 1790.96%. The net profit amount declined to ₹-99.99 Crore in March 2022 which increased to ₹1790.56 Crore in March 2023. The operating profit amount was ₹2,789.78 Crore in March 2022 which became ₹6,589.78 Crore in March 2023. If we look at the share price forecast of Sun Pharma Share Price Target 2025, the 1st Price Target is ₹1795 and the 2nd Price Target is ₹2010.

Sun Pharma Share Price Target 2027

Sun Pharma company has strong R&D capabilities for the development of product quality and innovative new products. The company mainly fixed targets to improve the quality of products like injectables, gels, sprays, orals, etc. In the financial year 2022, the investment amount in the R&D sector was ₹22.3 Billion and the amount was ₹21.6 Billion in the year 2021. The manufacturing facilities of Sun Pharma company are certified by European Medicines, UK Medicines, WHO, and many other international regulatory agencies.

Especially during the COVID-19 pandemic phase the sales growth of the company increasing rapidly. The last 5 years’ sales growth was 19.10% which increased to 19.89% in the last 3 years and the last year’s sales growth of the company increased to 34.12%. The net sales amount of the company was ₹15,789.56 Crore in March 2022 which became ₹20,932.56 Crore in March 2023. If we look at the share price forecast of Sun Pharma Share Price Target 2027 the 1st Price Target is ₹2580 and the 2nd Price Target is ₹2830.

Sun Pharma Share Price Target 2030

Sun Pharma Company is well established in the US market in the generic drug segment. From the US business segment, the company earned 30% consolidated revenue in the year 2022 and the amount was ₹115,836 Million in the year 2022. Sun Pharma company holds the 8th rank as the largest generic pharmaceutical company in the US. Some of the brands of the company are Molxvir, Pantocid, Garlic Pearls, Livcare, Nexito, etc.

As Sun Pharma is a very old company and has a market value of the products the promoter holding capacity of the company is good which is 55.12% which means many good investors want to invest in the share. As the company spreads its products outside of countries the FII investors of the company is good which is 17% to 18% which is good for the company’s growth. If we look at the share price forecast of Sun Pharma Share Price Target 2030 the 1st Price Target is ₹3510 and the 2nd Price Target is ₹3736.

Also Read – Suven Pharma Share Price Target

Sun Pharma Share Price Target 2040

Sun Pharma Company successfully overcame the COVID-19 pandemic situation by playing an important role. Supplying masks, sanitizers, Instant COVID-19 medicine, COVID-19 vaccine, etc which are also exported to different foreign countries for more development of the company’s economic condition. Sun Pharma Company spread its valuable products in 100 countries all over the world.

The total expenditure of the company was ₹15,986.56 Crore in March 2022 which became ₹20,896.56 Crore in March 2023. The tax amount was ₹408.23 Crore in March 2022 which became ₹50.89 Crore in March 2023. The ROE percentage of the company is not good the last 3 years ROE was 3.4% which was increased to 6.89% in the last 1 year. If we look at the share price forecast of Sun Pharma Share Price Target 2040 the 1st Price Target is ₹5996 and the 2nd Price Target is ₹6312.

How To Purchase Sun Pharma Share?

The most common trading platform for purchasing the Sun Pharma Share is described below.

• Zerodha
• Upstox
• Groww
• Angelone

Peer’s Company of Sun Pharma Company

• Cipla
• Divis Labs
• Lupin
• Mankind Pharma
• Zydus Life

Investors Types And Ratio Of Sun Pharma Company

There are mainly four Types of Investors in Sun Pharma Company. The company’s growth also depended upon the ratio of investors who invested in the share.

Promoters Holding

Promoters Holding means how much capital is invested by company promoters (owner of the company) through overall capital. Sun Pharma Company’s promoter holding capacity is 53.90%.

Public Holding

Public Investors are individuals who invest in the public market for profit in profit in the future (large and small companies). Sun Pharma Company’s public holding capacity is 9.80%.

FII

Foreign Institutional Investors are those big companies that invest in different countries company. Sun Pharma Company’s FII is 18.00%.

DII

Domestic Institutional Investors (like Insurance, companies mutual funds) who invest in their own country. Sun Pharma Company’s DII is 18.30%.

Advantages and Disadvantages Of Sun Pharma Share

Every share has some advantages and some disadvantages also. So, the Sun Pharma Share Price Target also has some advantages and disadvantages described below.

Advantages

• In the last 1 year, the company’s profit growth increased by 1790.96%.
• In the last 3 years, the company’s revenue growth has shown 18.92%.
• The company has an efficient cash conversation cycle which is -18.59 days.
• The cash flow management of the company is good which is 1.60.
• The book value amount per share has increased in the last 2 years.
• The company is increasing with a small amount of debt which will be easily recovered within a short period.

Disadvantages

• The company has a poor ROE ratio which is 3.4% in the last 3 years.
• The company has a high EBITDA which is 57.56%.
• The company shows a poor tax rate which is
• The company has a high PE ratio which is 380.23 which negatively affected the company’s growth.

Also Read – Yatharth Hospital Share Price Target

FAQ

Conclusion

Hopefully, www.sharetargethub.com will help you gain some basic ideas about the Sun Pharma Share Price Target. By doing the research and taking advice from expertise we ensure that on a long-term basis, Sun Pharma Share Price Target may reach a very high position. Sun Pharma Company is related to the pharmaceutical sector. So the demand for this sector also increases which helps the share to gain profit in the future.

If you think this website will be helpful for you then you can share it. If you have any questions please let us know through the comment box we will try to reply to your questions and solve your problem. Thanks for visiting this website and thanks for being with us.

Disclaimer – We are not SEBI-registered advisors. A financial market is always risky to anyone. This website is only for training and educational purposes. So before investing, we are requested to discuss certified expertise. We will not be responsible for anyone’s profit or loss.